Drug · Small Molecule

Foretinib

CI-DRUG-00000252Explore in graph →NCIt C80058 CHEMBL1230609 CIViC Phase 2

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Trials	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	10	—	—	Mar 17, 2005
Malignant Breast Neoplasm	Phase2	Phase 2	2	—	—	Sep 2, 2010
Malignant Kidney Neoplasm	Phase2	Phase 2	1	—	—	Jun 30, 2006
Malignant Liver Neoplasm	Phase1	Phase 1	1	—

Curated evidence

Clinical evidence (7)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–7 of 7 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ROS1 Fusion + ROS1 G2032R2
Foretinib	Lung Non-Small Cell Carcinoma

Clinical trials

Trials with this intervention (10)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–10 of 10 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01138384	Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer	completed	Phase 1 / Phase 2	19	NCIC Clinical Trials GroupNETWORK	1	Aug 4, 2023	clinicaltrials
NCT01147484	A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer(IND197)	completed

Molecule

Record

Kind: Small Molecule
Mechanism: Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor; Hepatocyte growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Tyrosine-protein kinase TIE-2 inhibitor; Vascular endothelial growth factor receptor inhibitor
Targets: 9 genes
Aliases: EXEL-2880, Foretinib, GSK-089, GSK089, Gsk-1363089, GSK-1363089, GSK1363089, GSK-1363089G, GSK1363089G, MET/VEGFR-2 Inhibitor GSK1363089, Multitargeted Tyrosine Kinase Inhibitor GSK1363089, N-(3-Fluoro-4-((6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, XL-880, XL880

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (0)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

Data not yet available

No cross-reference code recorded yet beyond the record identifiers above.

Regulatory status is jurisdiction-specific and time-bound. Nothing on this page is a treatment recommendation.

ROS1 Fusion + ROS1 G2101A1
Foretinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	accepted	EID1260 Ba/F3 cells expressing CD74–ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1, and were sensitive to foretinib. PMID 25688157 · Song et al., 2015 · Open in CIViC	civic

ROS1 Fusion + ROS1 G2101A1

Foretinib

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID1260

Ba/F3 cells expressing CD74–ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1, and were sensitive to foretinib.

PMID 25688157 · Song et al., 2015 · Open in CIViC

civic

ROS1 Fusion + ROS1 L2026M1
Foretinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	accepted	EID1258 Ba/F3 cells expressing CD74–ROS1 L2026M mutation showed similar sensitivity to foretinib compared with those expressing wild-type CD74–ROS1. This is in contrast to the increased resistance to crizotin… (full text at CIViC) PMID 25688157 · Song et al., 2015 · Open in CIViC	civic

ROS1 Fusion + ROS1 L2026M1

Foretinib

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID1258

Ba/F3 cells expressing CD74–ROS1 L2026M mutation showed similar sensitivity to foretinib compared with those expressing wild-type CD74–ROS1. This is in contrast to the increased resistance to crizotin… (full text at CIViC)

PMID 25688157 · Song et al., 2015 · Open in CIViC

civic

ROS1 Fusion + ROS1 L2155S1
ALK Inhibitor TAE684 + Crizotinib + ForetinibSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	3	accepted	EID1256 The L2155S mutation in ROS1 was identified in the HCC78CR1, -2 and -3 cell lines which harbor the SLC34A2–ROS1 rearrangement and in 2 patients with NSCLC with progressive disease following crizotinib … (full text at CIViC) PMID 25688157 · Song et al., 2015 · Open in CIViC	civic

ROS1 Fusion + ROS1 L2155S1

ALK Inhibitor TAE684 + Crizotinib + ForetinibSubstitutes

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Resistance

accepted

EID1256

The L2155S mutation in ROS1 was identified in the HCC78CR1, -2 and -3 cell lines which harbor the SLC34A2–ROS1 rearrangement and in 2 patients with NSCLC with progressive disease following crizotinib … (full text at CIViC)

PMID 25688157 · Song et al., 2015 · Open in CIViC

civic

CDH1 Loss1
Crizotinib + ForetinibSubstitutes	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	2	submitted	EID12768 In preclinical breast cancer models, including CRISPR-engineered E-cadherin-deficient MCF7 and MCF10A isogenic pairs, a 34-breast-cell-line siRNA and drug-screen panel, ex vivo breast cancer explants,… (full text at CIViC) PMID 29610289 · Bajrami et al., 2018 · Open in CIViC	civic

CDH1 Loss1

Crizotinib + ForetinibSubstitutes

Malignant Breast Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID12768

In preclinical breast cancer models, including CRISPR-engineered E-cadherin-deficient MCF7 and MCF10A isogenic pairs, a 34-breast-cell-line siRNA and drug-screen panel, ex vivo breast cancer explants,… (full text at CIViC)

PMID 29610289 · Bajrami et al., 2018 · Open in CIViC

civic

MET Mutation1
Foretinib	Papillary Renal Cell Carcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID796 In a retrospective analysis of 74 patients with papillary renal cell carcinoma, treated with foretinib, MET germline mutation was associated with improved response rate. A response was observed in 5 … (full text at CIViC) PMID 23213094 · Choueiri et al., 2013 · Open in CIViC	civic

MET Mutation1

Foretinib

Papillary Renal Cell Carcinoma

Predictive

Supports Sensitivity Response

accepted

EID796

In a retrospective analysis of 74 patients with papillary renal cell carcinoma, treated with foretinib, MET germline mutation was associated with improved response rate. A response was observed in 5 … (full text at CIViC)

PMID 23213094 · Choueiri et al., 2013 · Open in CIViC

civic